Doxorubicin-Loaded Glycyrrhetinic Acid Modified Recombinant Human Serum Albumin Nanoparticles for Targeting Liver Tumor Chemotherapy

Molecular Pharmaceutics

Volumn 12, Issue 3, 2015, Pages 675-683

  Qi, Wen Wen ^a   Yu, Hai Yan ^a   Guo, Hui ^a   Lou, Jun ^a   Wang, Zhi Ming ^a   Liu, Peng ^a   Sapin Minet, Anne ^b   Maincent, Philippe ^b   Hong, Xue Chuan ^a   Hu, Xian Ming ^a   Xiao, Yu Ling ^a  

^a WUHAN UNIVERSITY   (China)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

glycyrrhetinic acid; liver cancer targeting; nanoparticle; recombinant human serum albumin

Indexed keywords

DAUNORUBICIN; DOXORUBICIN; GLYCYRRHETINIC ACID; HUMAN SERUM ALBUMIN; NANOPARTICLE; RECOMBINANT HUMAN SERUM ALBUMIN; ANTINEOPLASTIC AGENT; NANOCAPSULE; RECOMBINANT PROTEIN; SERUM ALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; DRUG TARGETING; ENCAPSULATION; HUMAN; HUMAN CELL; LIVER CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG SCREENING; HELA CELL LINE; HEPG2 CELL LINE; LIVER NEOPLASMS, EXPERIMENTAL; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUDE MOUSE; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; GLYCYRRHETINIC ACID; HELA CELLS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOCAPSULES; RECOMBINANT PROTEINS; SERUM ALBUMIN; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924366164     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500394v     Document Type: Article

References (43)

1. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy Nat. Nano 2007, 2 (12) 751 - 60
2. Kumar, A.; Chen, F.; Mozhi, A.; Zhang, X.; Zhao, Y.; Xue, X.; Hao, Y.; Zhang, X.; Wang, P. C.; Liang, X. J. Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation Nanoscale 2013, 5 (18) 8307 - 25
3. Wagner, S.; Rothweiler, F.; Anhorn, M. G.; Sauer, D.; Riemann, I.; Weiss, E. C.; Katsen-Globa, A.; Michaelis, M.; Cinatl, J., Jr.; Schwartz, D.; Kreuter, J.; von Briesen, H.; Langer, K. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles Biomaterials 2010, 31 (8) 2388 - 98
4. Cho, K.; Wang, X.; Nie, S.; Chen, Z.; Shin, D. M. Therapeutic Nanoparticles for Drug Delivery in Cancer Clin. Cancer Res. 2008, 14 (5) 1310 - 6
5. Varshney, A.; Sen, P.; Ahmad, E.; Rehan, M.; Subbarao, N.; Khan, R. H. Ligand binding strategies of human serum albumin: how can the cargo be utilized? Chirality 2010, 22 (1) 77 - 87
6. Kobayashi, K. Summary of recombinant human serum albumin development Biologicals 2006, 34 (1) 55 - 9
7. Weber, C.; Coester, C.; Kreuter, J.; Langer, K. Desolvation process and surface characterisation of protein nanoparticles Int. J. Pharm. 2000, 194 (1) 91 - 102
8. Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Controlled Release 2008, 132 (3) 171 - 83
9. Jiang, S.; Win, K. Y.; Liu, S.; Teng, C. P.; Zheng, Y.; Han, M. Y. Surface-functionalized nanoparticles for biosensing and imaging-guided therapeutics Nanoscale 2013, 5 (8) 3127 - 48
10. An, N.; Ou, J.; Jiang, D.; Zhang, L.; Liu, J.; Fu, K.; Dai, Y.; Yang, D. Expression of a functional recombinant human basic fibroblast growth factor from transgenic rice seeds Int. J. Mol. Sci. 2013, 14 (2) 3556 - 67
11. Chen, Z.; He, Y.; Shi, B.; Yang, D. Human serum albumin from recombinant DNA technology: challenges and strategies Biochim. Biophys. Acta 2013, 1830 (12) 5515 - 25
12. He, Y.; Ning, T.; Xie, T.; Qiu, Q.; Zhang, L.; Sun, Y.; Jiang, D.; Fu, K.; Yin, F.; Zhang, W.; Shen, L.; Wang, H.; Li, J.; Lin, Q.; Sun, Y.; Li, H.; Zhu, Y.; Yang, D. Large-scale production of functional human serum albumin from transgenic rice seeds Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (47) 19078 - 83 10.1073/pnas.1109736108
13. Zhang, L.; Shi, J.; Jiang, D.; Stupak, J.; Ou, J.; Qiu, Q.; An, N.; Li, J.; Yang, D. Expression and characterization of recombinant human alpha-antitrypsin in transgenic rice seed J. Biotechnol. 2012, 164 (2) 300 - 8
14. Wu, H.; Zhu, L.; Torchilin, V. P. pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery Biomaterials 2013, 34 (4) 1213 - 22
15. Greenwald, R. B. PEG drugs: an overview J. Controlled Release 2001, 74 (1-3) 159 - 71
16. Xu, S.; Olenyuk, B. Z.; Okamoto, C. T.; Hamm-Alvarez, S. F. Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances Adv. Drug Delivery Rev. 2013, 65 (1) 121 - 38
17. Nobs, L.; Buchegger, F.; Gurny, R.; Allémann, E. Current methods for attaching targeting ligands to liposomes and nanoparticles J. Pharm. Sci. 2004, 93 (8) 1980 - 92
18. Heukers, R.; Altintas, I.; Raghoenath, S.; De Zan, E.; Pepermans, R.; Roovers, R. C.; Haselberg, R.; Hennink, W. E.; Schiffelers, R. M.; Kok, R. J.; van Bergen en Henegouwen, P. M. Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles Biomaterials 2014, 35 (1) 601 - 10
19. Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O. C. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology Adv. Drug Delivery Rev. 2014, 66, 2 - 25 10.1016/j.addr.2013.11.009
20. Lin, W.; Garnett, M. C.; Davies, M. C.; Bignotti, F.; Ferruti, P.; Davis, S. S.; Illum, L. Preparation of surface-modified albumin nanospheres Biomaterials 1997, 18 (7) 559 - 65
21. Kim, T. H.; Jiang, H. H.; Youn, Y. S.; Park, C. W.; Lim, S. M.; Jin, C. H.; Tak, K. K.; Lee, H. S.; Lee, K. C. Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution J. Pharm. Sci. 2011, 100 (2) 482 - 91
22. Ulbrich, K.; Michaelis, M.; Rothweiler, F.; Knobloch, T.; Sithisarn, P.; Cinatl, J.; Kreuter, J. Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells Int. J. Pharm. 2011, 406 (1-2) 128 - 34
23. Zhao, D.; Zhao, X.; Zu, Y.; Li, J.; Zhang, Y.; Jiang, R.; Zhang, Z. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles Int. J. Nanomed. 2010, 5, 669 - 77
24. Li, Q.; Liu, C.; Zhao, X.; Zu, Y.; Wang, Y.; Zhang, B.; Zhao, D.; Zhao, Q.; Su, L.; Gao, Y.; Sun, B. Preparation, characterization and targeting of micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles to cancer cells Int. J. Nanomed. 2011, 6, 397 - 405
25. Ferrari, M. Cancer nanotechnology: opportunities and challenges Nat. Rev. Cancer 2005, 5 (3) 161 - 71
26. Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics Adv. Drug Delivery Rev. 2008, 60 (15) 1615 - 26
27. Zhang, C.; Wang, W.; Liu, T.; Wu, Y.; Guo, H.; Wang, P.; Tian, Q.; Wang, Y.; Yuan, Z. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy Biomaterials 2012, 33 (7) 2187 - 96
28. Huang, W.; Wang, W.; Wang, P.; Tian, Q.; Zhang, C.; Wang, C.; Yuan, Z.; Liu, M.; Wan, H.; Tang, H. Glycyrrhetinic acid-modified poly(ethylene glycol)-b-poly(gamma-benzyl l-glutamate) micelles for liver targeting therapy Acta Biomater. 2010, 6 (10) 3927 - 35
29. Tian, Q.; Wang, X. H.; Wang, W.; Zhang, C. N.; Wang, P.; Yuan, Z. Self-assembly and liver targeting of sulfated chitosan nanoparticles functionalized with glycyrrhetinic acid Nanomedicine 2012, 8 (6) 870 - 9
30. Huang, W.; Wang, W.; Wang, P.; Zhang, C. N.; Tian, Q.; Zhang, Y.; Wang, X. H.; Cha, R. T.; Wang, C. H.; Yuan, Z. Glycyrrhetinic acid-functionalized degradable micelles as liver-targeted drug carrier J. Mater. Sci. Mater. Med. 2011, 22 (4) 853 - 63
31. He, Z. Y.; Zheng, X.; Wu, X. H.; Song, X. R.; He, G.; Wu, W. F.; Yu, S.; Mao, S. J.; Wei, Y. Q. Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery Int. J. Pharm. 2010, 397 (1-2) 147 - 54
32. Shi, L.; Tang, C.; Yin, C. Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma Biomaterials 2012, 33 (30) 7594 - 604
33. Lin, A.; Liu, Y.; Huang, Y.; Sun, J.; Wu, Z.; Zhang, X.; Ping, Q. Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery Int. J. Pharm. 2008, 359 (1-2) 247 - 53
34. Tian, Q.; Wang, W.; He, X.; Zhu, X.; Huang, W.; Zhang, C.; Yuan, Z.; Chen, X. Glycyrrhetinic acid-modified nanoparticles for drug delivery: Preparation and characterization Chin. Sci. Bull. 2009, 54 (18) 3121 - 6
35. Langer, K.; Balthasar, S.; Vogel, V.; Dinauer, N.; von Briesen, H.; Schubert, D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles Int. J. Pharm. 2003, 257 (1-2) 169 - 80
36. Urva, S. R.; Shin, B. S.; Yang, V. C.; Balthasar, J. P. Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2009, 877 (8-9) 837 - 41
37. Verdun, C.; Brasseur, F.; Vranckx, H.; Couvreur, P.; Roland, M. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles Cancer Chemother. Pharmacol. 1990, 26 (1) 13 - 8
38. Al-Abd, A. M.; Kim, N. H.; Song, S. C.; Lee, S. J.; Kuh, H. J. A simple HPLC method for doxorubicin in plasma and tissues of nude mice Arch. Pharm. Res. 2009, 32 (4) 605 - 11
39. Tian, Q.; Wang, X.; Wang, W.; Zhang, C.; Liu, Y.; Yuan, Z. Insight into glycyrrhetinic acid: the role of the hydroxyl group on liver targeting Int. J. Pharm. 2010, 400 (1-2) 153 - 7
40. Jun, J. Y.; Nguyen, H. H.; Paik, S.-Y.-R.; Chun, H. S.; Kang, B.-C.; Ko, S. Preparation of size-controlled bovine serum albumin (BSA) nanoparticles by a modified desolvation method Food Chem. 2011, 127 (4) 1892 - 8
41. Prabaharan, M.; Grailer, J. J.; Pilla, S.; Steeber, D. A.; Gong, S. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery Biomaterials 2009, 30 (29) 5757 - 66
42. Gillies, E. R.; Frechet, J. M. pH-Responsive copolymer assemblies for controlled release of doxorubicin Bioconjugate Chem. 2005, 16 (2) 361 - 8
43. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv. Enzyme Regul. 2001, 41, 189 - 207